{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057121","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.332647+00:00","generated_at":"2026-06-09T03:48:27.126655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amarin Q3 2023: Revenue $66M (-27% YoY), net loss $19.3M; cash flow +$8M","bullets":["Total net revenue $66.1M, down 27% vs Q3 2022; net loss $19.3M vs $5.1M loss a year ago; diluted EPS loss $0.05.","U.S. net product revenue $62.4M (-3% sequentially); maintained ~57% IPE market share despite generic competition.","European revenue $0.8M; early launches in UK, Spain, Netherlands with progress under new leadership.","Generated $8M positive cash flow in quarter; cash and investments $321M; on track for $40M annual savings from July restructuring.","Partner Edding launched VASCEPA in China for severe hypertriglyceridemia; submitted CVRR indication filing to NMPA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057121","json":"https://secwatch.observer/filing/0000950170-23-057121.json","markdown":"https://secwatch.observer/filing/0000950170-23-057121.md","text":"https://secwatch.observer/filing/0000950170-23-057121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017023057121/0000950170-23-057121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017023057121/amrn-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:48:27.126655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c21a3f3ec967979a1a33780f5510669466836ab3","claim":"AMARIN CORP PLCUK reported three and nine months ended September 30, 2023 results: revenue Total net revenue for the three months ended September 30, 2023, was $66.1 million.","evidence_excerpt":"Total net revenue for the three months ended September 30, 2023, was $66.1 million, compared to $89.9 million in the corresponding period of 2022, a decrease of 27%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017023057121/0000950170-23-057121-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Revenue","value":"Total net revenue for the three months ended September 30, 2023, was $66.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}